Literature DB >> 20427388

COX-2 expression in adenoma: an imperfect marker for chemoprevention.

Andrew T Chan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20427388      PMCID： PMC2947550          DOI： 10.1136/gut.2009.200014

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  13 in total

1.  A randomized trial of aspirin to prevent colorectal adenomas.

Authors:  John A Baron; Bernard F Cole; Robert S Sandler; Robert W Haile; Dennis Ahnen; Robert Bresalier; Gail McKeown-Eyssen; Robert W Summers; Richard Rothstein; Carol A Burke; Dale C Snover; Timothy R Church; John I Allen; Michael Beach; Gerald J Beck; John H Bond; Tim Byers; E Robert Greenberg; Jack S Mandel; Norman Marcon; Leila A Mott; Loretta Pearson; Fred Saibil; Rosalind U van Stolk
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

2.  A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer.

Authors:  Robert S Sandler; Susan Halabi; John A Baron; Susan Budinger; Electra Paskett; Roger Keresztes; Nicholas Petrelli; J Marc Pipas; Daniel D Karp; Charles L Loprinzi; Gideon Steinbach; Richard Schilsky
Journal:  N Engl J Med       Date:  2003-03-06       Impact factor: 91.245

3.  MGMT promoter methylation and field defect in sporadic colorectal cancer.

Authors:  Lanlan Shen; Yutaka Kondo; Gary L Rosner; Lianchun Xiao; Natalie Supunpong Hernandez; Jill Vilaythong; P Scott Houlihan; Robert S Krouse; Anil R Prasad; Janine G Einspahr; Julie Buckmeier; David S Alberts; Stanley R Hamilton; Jean-Pierre J Issa
Journal:  J Natl Cancer Inst       Date:  2005-09-21       Impact factor: 13.506

4.  Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention.

Authors:  Robert Benamouzig; Bernard Uzzan; Antoine Martin; Jacques Deyra; Julian Little; Bernard Girard; Stanislas Chaussade
Journal:  Gut       Date:  2010-05       Impact factor: 23.059

5.  Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

Authors:  Bernard F Cole; Richard F Logan; Susan Halabi; Robert Benamouzig; Robert S Sandler; Matthew J Grainge; Stanislas Chaussade; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

6.  Aspirin and folic acid for the prevention of recurrent colorectal adenomas.

Authors:  Richard F A Logan; Matthew J Grainge; Vic C Shepherd; Nicholas C Armitage; Kenneth R Muir
Journal:  Gastroenterology       Date:  2007-10-10       Impact factor: 22.682

7.  Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial.

Authors:  Robert Benamouzig; Jacques Deyra; Antoine Martin; Bernard Girard; Eric Jullian; Benoit Piednoir; Daniel Couturier; Thierry Coste; Julian Little; Stanislas Chaussade
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

8.  Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas.

Authors:  C E Eberhart; R J Coffey; A Radhika; F M Giardiello; S Ferrenbach; R N DuBois
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

9.  15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.

Authors:  Min Yan; Seung-Jae Myung; Stephen P Fink; Earl Lawrence; James Lutterbaugh; Peiying Yang; Xiaohua Zhou; Danielle Liu; Ronald M Rerko; Joseph Willis; Dawn Dawson; Hsin-Hsiung Tai; Jill S Barnholtz-Sloan; Robert A Newman; Monica M Bertagnolli; Sanford D Markowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-22       Impact factor: 11.205

10.  Aspirin use and survival after diagnosis of colorectal cancer.

Authors:  Andrew T Chan; Shuji Ogino; Charles S Fuchs
Journal:  JAMA       Date:  2009-08-12       Impact factor: 56.272
View more
  3 in total

1.  Comparison of biomarker expression between proximal and distal colorectal adenomas: The Tennessee-Indiana Adenoma Recurrence Study.

Authors:  Timothy Su; M Kay Washington; Reid M Ness; Douglas K Rex; Walter E Smalley; Thomas M Ulbright; Qiuyin Cai; Wei Zheng; Martha J Shrubsole
Journal:  Mol Carcinog       Date:  2016-08-11       Impact factor: 4.784

2.  Evaluation of malignancy using Ki-67, p53, EGFR and COX-2 expressions in gastrointestinal stromal tumors.

Authors:  Jing Jiang; Mei-Shan Jin; Jian Suo; Yin-Ping Wang; Liang He; Xue-Yuan Cao
Journal:  World J Gastroenterol       Date:  2012-05-28       Impact factor: 5.742

3.  Impact of cyclooxygenase-2 over-expression on the prognosis of colorectal cancer patients. An experience from Western Saudi Arabia.

Authors:  Abdulkader M Albasri; Mohammed A Elkablawy; Akbar S Hussainy; Hala M Yousif; Ahmed S Alhujaily
Journal:  Saudi Med J       Date:  2018-08       Impact factor: 1.484
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.